Literature DB >> 21080547

Eptifibatide is noninferior to abciximab: implications for clinical practice.

Alexandra King.   

Abstract

Year:  2010        PMID： 21080547     DOI： 10.1038/nrcardio.2010.128

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

Authors:  Uwe Zeymer; Alain Margenet; Michael Haude; Christoph Bode; Jean-Marc Lablanche; Hubertus Heuer; Rolf Schröder; Stefan Kropff; Ryad Bourkaib; Norbert Banik; Ralf Zahn; Emmanuel Teiger
Journal:  J Am Coll Cardiol       Date:  2010-08-03       Impact factor: 24.094

2.  Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

Authors:  Axel Akerblom; Stefan K James; Michail Koutouzis; Bo Lagerqvist; Ulf Stenestrand; Bodil Svennblad; Jonas Oldgren
Journal:  J Am Coll Cardiol       Date:  2010-08-03       Impact factor: 24.094
  2 in total
  1 in total

Review 1.  Integrins as Therapeutic Targets: Successes and Cancers.

Authors:  Sabine Raab-Westphal; John F Marshall; Simon L Goodman
Journal:  Cancers (Basel)       Date:  2017-08-23       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.